Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor” inside PodZeus.
In this episode of Business Of Biotech, host Ben Comer interviews Thijs Spoor, CEO of Perspective Therapeutics, a clinical-stage radiopharmaceutical company developing targeted alpha-emitting therapies using lead-212 (Pb-212). Spoor shares his journey from pharmacy school to Wall Street and back into nuclear medicine, highlighting the evolution of radiopharmaceuticals from diagnostic tools to disease-modifying therapies. He discusses the transformative impact of drugs like Lutathera and Pluvicto, which demonstrated that targeted radiotherapy could significantly improve outcomes for patients with neuroendocrine tumors and prostate cancer. A major focus of the conversation is Perspective Therapeutics’ proprietary Pb-212 generator, which enables reliable, scalable production of alpha-emitting therapeutics—a critical advantage in a supply chain historically constrained by limited isotope availability. Spoor emphasizes the company’s strategic vertical integration, including regional manufacturing hubs across the U.S. to ensure reliable, same-day delivery to cancer centers. He also explores the future of alpha-emitting isotopes, the importance of biodistribution and chelator design, and the company’s pipeline targeting SSTR2-positive tumors, melanoma, and FAP-expressing cancers. The episode concludes with Spoor outlining key 2026 milestones, including first-in-human imaging data, clinical data readouts, and the completion of a state-of-the-art manufacturing facility in Chicago.
Perspective Therapeutics has developed a proprietary Pb-212 generator, enabling reliable, scalable production of alpha-emitting radiotherapeutics and reducing reliance on scarce external supply chains.
Alpha-emitting isotopes like Pb-212 are highly potent—just one particle can kill a cancer cell—but require precise targeting to avoid off-target damage, making biodistribution and chelator design critical.
The company is building a network of regional manufacturing sites across the U.S. to ensure same-day delivery to cancer centers, improving supply chain resilience over centralized models.
Perspective’s pipeline focuses on receptor-targeted therapies (e.g., SSTR2, MC1R, FAP) rather than organ-specific cancers, allowing broader applicability across tumor types that express the target.
Combining alpha radiotherapy with immune checkpoint inhibitors (e.g., nivolumab) shows promise by triggering a neoantigenic storm that enhances immune system activation.
Introduction to Perspective Therapeutics and Thijs Spoor's Background
Host Ben Comer introduces Thijs Spoor, CEO of Perspective Therapeutics, and explores his journey from pharmacy school at the University of Toronto to Wall Street and back into nuclear medicine. Spoor shares how his early fascination with nuclear pharmacy led to a career spanning global commercialization of radiopharmaceuticals at Amersham and GE Healthcare.
The Evolution of Radiopharmaceuticals: From Diagnostics to Therapeutics
“The field thought okay where can we make a difference? We can image a tumor but we can also treat a tumor. And that's where it got really exciting.”
The Strategic Importance of Pb-212 and the Proprietary Generator
“We didn't want to jump into that space, but we realized that no one had the know-how necessary to make the isotopes in a safe, consistent fashion. So we did it because we had to.”
Regional Manufacturing and Supply Chain Resilience
“A network with multiple nodes is always more reliable than a single point of failure with a single distribution hub.”
Alpha vs. Beta Emitters and the Future of Targeted Radiotherapy
Spoor compares alpha and beta emitters, emphasizing the superior potency of alpha particles (one particle kills a cancer cell) but also their higher risk of off-target damage. He discusses the importance of chelator design to control daughter isotopes and ensure tumor-specific delivery. He argues that alpha therapy will be central to future radiotherapeutics, especially when paired with immune checkpoint inhibitors.
“We didn't want to jump into that space, but we realized that no one had the know-how necessary to make the isotopes in a safe, consistent fashion. So we did it because we had to.”
“The field thought okay where can we make a difference? We can image a tumor but we can also treat a tumor. And that's where it got really exciting.”
“You need to really make sure that the alphas, if you're using them, are only going to tumor because if they're going somewhere else, then you're going to cause a lot of extra damage.”
Host
Guest
Perspective Therapeutics
organization
lead-212
other
Thijs Spoor
person
GE Healthcare
organization
Lutathera
product
SSTR2
other
Pluvicto
product
Amersham International
organization
Chicago
place
University of Toronto
other
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime